Synthesis and In-silico design of a novel silver metal ciprofloxacin compound

Abstract

Ciprofloxacin is a quinolone derivative with antibacterial properties. Quinolones, which share structural similarities with nalidixic acid, function as unidentate, bidentate, and bridging ligands during chelation. A key factor in increasing quinolones' biological activity is the presence of metal ions. Many transition metals, including Ni2+, Co2+, Ca2+, Zn2+, Ag2+, Au2+, Mn2+, Mg2+, and Fe2+, are often utilised as chelating agents. The ciprofloxacin silver ions was developed in the current study and then compared with two standard medications (ciprofloxacin and norfloxacin) and evaluated for in-silico investigations using (PDB ID: 2XCT). It was shown that the silver metal of the ciprofloxacin Analogue (L1) had a higher docking score and glide energy when compared to two standard medications like, norfloxacin and ciprofloxacin respectively. It has been demonstrated in in-silico studies that the synthesised novel silver metal of the ciprofloxacin analogue (L1) has significant potency against a wide range of bacterial and fungal diseases, making it an essential source for new antibacterial drugs that target bacterial and fungal diseases in the future.